|
Tabla 7: Proporciones agrupadas de resistencia a los antibióticos para Acinetobacter baumanii. |
||||||
|
Resistencia % |
General N = 504 n (%) |
2020 N = 84 n (%) |
2021 N = 88 n (%) |
2022 N = 152 n (%) |
2023 N = 116 n (%) |
2024 N = 63 n (%) |
|
Ampicilina- sulbactam |
222 (44.0) |
41 (48.8) |
41 (46.6) |
54 (35.5) |
51 (44.0) |
35 (55.6) |
|
Ceftriaxona |
313 (62.1) |
57 (67.9) |
55 (62.5) |
81 (53.3) |
75 (64.7) |
45 (70.3) |
|
Cefotaxima |
369 (73.2) |
62 (73.8) |
65 (73.9) |
105 (69.1) |
85 (73.3) |
52 (81.0) |
|
Ciprofloxacino |
157 (31.2) |
17 (20.2) |
28 (31.8) |
42 (27.6) |
37 (31.9) |
33 (52.4) |
|
Gentamicina |
142 (28.2) |
25 (29.8) |
31 (35.2) |
28 (18.4) |
33 (28.4) |
25 (39.7) |
|
Levofloxacino |
196 (38.9) |
30 (35.7) |
29 (33.0) |
50 (32.9) |
58 (50.0) |
29 (44.4) |
|
Piperacilina- tazobactam |
140 (27.8) |
31 (36.9) |
23 (26.1) |
38 (25.0) |
26 (22.4) |
22 (34.9) |
|
Trimetoprima sulfametoxazol |
234 (46.4) |
39 (46.4) |
47 (53.4) |
60 (39.5) |
57 (49.1) |
31 (47.8) |
|
Amikacina |
242 (48.0) |
41 (48.8) |
45 (51.1) |
66 (43.4) |
58 (50.0) |
32 (50.0) |
|
Cefepima |
174 (34.5) |
31 (36.9) |
30 (34.1) |
36 (23.7) |
43 (37.1) |
34 (54.0) |
|
Imipenem |
157 (31.2) |
26 (31.0) |
11 (12.5) |
55 (36.2) |
30 (25.8) |
35 (55.6) |
|
Meropenem |
145 (28.8) |
20 (23.8) |
17 (19.3) |
46 (30.3) |
43 (37.1) |
46 (30.0) |
|
Tobramicina |
256 (50.8) |
41 (48.8) |
47 (53.4) |
71 (46.7) |
60 (51.7) |
37 (57.3) |
|
Ceftazidima |
162 (32.1) |
34 (40.5) |
31 (35.2) |
35 (23.0) |
26 (22.4) |
36 (57.1) |